Rapport Therapeutics (RAPP) Institutional Ownership $8.52 -1.44 (-14.46%) Closing price 04:00 PM EasternExtended Trading$8.49 -0.03 (-0.29%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Rapport Therapeutics (NASDAQ:RAPP)Number ofInstitutional Buyers(last 12 months)39TotalInstitutional Inflows(last 12 months)$168.90MNumber ofInstitutional Sellers(last 12 months)6TotalInstitutional Outflows(last 12 months)$2.70M Get RAPP Insider Trade Alerts Want to know when executives and insiders are buying or selling Rapport Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data RAPP Institutional Buying and Selling by Quarter Remove Ads Rapport Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails3/18/2025California State Teachers Retirement System8,571$152K0.0%+1,151.2%0.023% 2/17/2025Woodline Partners LP181,530$3.22M0.0%-2.7%0.496% 2/17/2025Deutsche Bank AG2,317$41K0.0%N/A0.006% 2/17/2025Crestline Management LP27,496$488K0.0%N/A0.075% 2/17/2025Bank of America Corp DE6,578$117K0.0%-65.6%0.018% 2/17/2025Acuta Capital Partners LLC16,400$291K0.3%-6.8%0.045% 2/14/2025Virtus ETF Advisers LLC3,740$66K0.0%N/A0.010% 2/14/2025T. Rowe Price Investment Management Inc.1,636,931$29.04M0.0%-5.2%4.475% 2/14/2025Price T Rowe Associates Inc. MD1,143,384$20.29M0.0%+9.2%3.126% 2/14/2025TRV GP V LLC7,135,233$126.58M43.1%N/A19.506% Get the Latest News and Ratings for RAPP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Rapport Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/14/2025TRV GP VI LLC969,218$17.19M14.7%N/A2.650% 2/13/2025Barclays PLC18,497$328K0.0%+43.8%0.051% 2/13/2025Legal & General Group Plc9,523$169K0.0%+947.6%0.026% 2/13/2025Wells Fargo & Company MN4,824$86K0.0%+38.9%0.013% 2/12/2025Geode Capital Management LLC210,676$3.74M0.0%+4.4%0.576% 2/12/2025Alliancebernstein L.P.1,098,415$19.49M0.0%+0.9%3.003% 2/12/2025Norges Bank48,452$860K0.0%N/A0.132% 2/12/2025JPMorgan Chase & Co.7,170$127K0.0%+77.8%0.020% 2/11/2025KLP Kapitalforvaltning AS1,900$34K0.0%N/A0.005% 2/10/2025Swiss National Bank18,000$319K0.0%N/A0.049% 1/31/2025New York State Common Retirement Fund3,500$62K0.0%N/A0.010% 1/30/2025Rhumbline Advisers10,249$182K0.0%-35.3%0.028% 1/24/2025Jennison Associates LLC62,287$1.11M0.0%N/A0.170% 1/24/2025China Universal Asset Management Co. Ltd.7,756$138K0.0%N/A0.021% 12/26/2024JPMorgan Chase & Co.4,033$83K0.0%N/A0.011% 11/19/2024Barclays PLC12,863$264K0.0%+36.8%0.035% 11/16/2024Geode Capital Management LLC201,748$4.13M0.0%N/A0.552% 11/15/2024Barclays PLC12,863$264K0.0%+36.8%0.035% 11/15/2024State Street Corp58,046$1.19M0.0%N/A0.159% 11/15/2024Maven Securities LTD29,930$613K0.0%N/A0.082% 11/14/2024Eventide Asset Management LLC110,401$2.26M0.0%+120.8%0.302% 11/14/2024Acuta Capital Partners LLC17,600$360K0.3%-12.0%0.048% 11/14/2024MetLife Investment Management LLC5,710$117K0.0%N/A0.016% 11/13/2024BNP Paribas Financial Markets1,684$34K0.0%N/A0.005% 11/13/2024FMR LLC5,486,468$112.36M0.0%+10.1%14.999% 11/13/2024The Manufacturers Life Insurance Company77,344$1.58M0.0%+2.4%0.211% 11/12/2024Charles Schwab Investment Management Inc.73,146$1.50M0.0%N/A0.200% 11/7/2024LMR Partners LLP20,000$410K0.0%-60.0%0.055% 10/23/2024Values First Advisors Inc.1,507$31K0.0%N/A0.004% 10/3/2024SG Americas Securities LLC4,934$101K0.0%N/A0.014% [Action Required] Claim Your FREE IRS Loophole Guide (Ad)This shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the biggest "dollar reset" since 1971.So claim your FREE copy of this 2025 Gold Guide to learn more.8/27/2024Logos Global Management LP208,910$4.86M0.4%N/A0.591% 8/16/2024Perceptive Advisors LLC748,183$17.40M0.4%N/A2.045% 8/15/2024The Manufacturers Life Insurance Company75,516$1.76M0.0%N/A0.206% 8/15/2024Millennium Management LLC116,782$2.72M0.0%N/A0.319% 8/14/2024Squarepoint Ops LLC16,345$380K0.0%N/A0.045% 8/14/2024Sandia Investment Management LP5,000$116K0.2%N/A0.014% 8/14/2024ARCH Venture Management LLC3,728,738$86.73M31.6%N/A10.193% 8/14/2024Davidson Kempner Capital Management LP10,000$229K0.0%N/A0.027% 8/10/2024Sofinnova Investments Inc.1,951,562$45.39M2.4%N/A5.516% 8/9/2024Johnson & Johnson2,498,051$58.11M14.5%N/A7.061% 8/3/2024TD Asset Management Inc101,522$2.36M0.0%N/A0.287% (Data available from 1/1/2016 forward)Remove Ads RAPP Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of RAPP shares? During the previous two years, 45 institutional investors and hedge funds held shares of Rapport Therapeutics. The most heavily invested institutionals were TRV GP V LLC ($126.58M), FMR LLC ($112.36M), ARCH Venture Management LLC ($86.73M), Johnson & Johnson ($58.11M), Sofinnova Investments Inc. ($45.39M), T. Rowe Price Investment Management Inc. ($29.04M), and Price T Rowe Associates Inc. MD ($20.29M).Learn more on RAPP's institutional investors. Which institutional investors have been buying Rapport Therapeutics stock? Of the 39 institutional investors that purchased Rapport Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: TRV GP V LLC ($7.14M), ARCH Venture Management LLC ($3.73M), Johnson & Johnson ($2.50M), Sofinnova Investments Inc. ($1.95M), TRV GP VI LLC ($969.22K), Perceptive Advisors LLC ($748.18K), and FMR LLC ($503.12K). How much institutional buying is happening at Rapport Therapeutics? Institutional investors have bought a total of 18,834,539 shares in the last 24 months. This purchase volume represents approximately $168.90M in transactions. Which Rapport Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Rapport Therapeutics stock in the last 24 months: T. Rowe Price Investment Management Inc. ($90.18K), LMR Partners LLP ($30K), Bank of America Corp DE ($12.53K), Rhumbline Advisers ($5.59K), Woodline Partners LP ($5.03K), and Acuta Capital Partners LLC ($3.60K). How much institutional selling is happening at Rapport Therapeutics? Institutional investors have sold a total of 146,936 shares in the last 24 months. This volume of shares sold represents approximately $2.70M in transactions. Related Companies ANIP Institutional Ownership SDGR Institutional Ownership IDYA Institutional Ownership AMPH Institutional Ownership INDV Institutional Ownership DYN Institutional Ownership WVE Institutional Ownership SPRY Institutional Ownership CALT Institutional Ownership EVO Institutional Ownership This page (NASDAQ:RAPP) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RAPP Stock Free RAPP Stock Alerts